Puma Biotechnology Inc (NASDAQ: PBYI) popped 88 percent Monday on news that its neratinib candidate, an early-stage breast cancer treatment for human epidermal growth factor receptor-2 (HER2)
May 23, 2017 at 06:05PM
from Elizabeth Balboa
Featured Post
Twenty Practical Steps to Better Corporate Governance | The Corporate Secretaries International Association (CSIA)
Twenty Practical Steps to Better Corporate Governance | The Corporate Secretaries International Association (CSIA) Please click the li...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment